SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies Inc. (OTC BB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies and diagnostics, announced today that Status Equity Research has initiated research coverage on the Company with a rating of Accumulate and a 36 month price target of $16 per share.
